Source comparison
CJC-1295 No DAC vs DAC-Modified vs Other Secretagogues: Recovery Research Comparison
CJC-1295 No DAC 6–8 days 6–8 days sustained Reversible GHRH receptor agonism Full washout in 10–14 days Longitudinal recovery studies requiring consistent GH without permanent changes Requires weekly dosing; not suitable for acute pulsatile studies CJC-1295 Wi
This comparison does not assign a generated winner or score.
- CJC-1295 No DAC
- 6–8 days
- 6–8 days sustained
- Reversible GHRH receptor agonism
- Full washout in 10–14 days
- Longitudinal recovery studies requiring consistent GH without permanent changes
- Requires weekly dosing; not suitable for acute pulsatile studies
- CJC-1295 With DAC
- 7–14 days initial, weeks-long receptor occupancy
- Weeks to months
- Covalent GHRH receptor binding
- No. Permanent modification
- Chronic metabolic studies where ongoing GH elevation is desired
- Cannot be reversed; eliminates washout-phase observations
- Sermorelin
- 7–10 minutes
- 90–120 minutes post-dose
- Standard GHRH receptor agonism
- Immediate clearance
- Acute GH pulse studies; circadian rhythm research
- Requires multiple daily doses; high variability in plasma levels
- Ipamorelin
- 2 hours
- 2–4 hours
- Ghrelin receptor agonism (not GHRH pathway)
- Rapid clearance
- Appetite/GI motility research; short-term GH studies
- Different receptor target; does not replicate GHRH-mediated signaling
- Recombinant hGH
- 2–3 hours
- 12–24 hours (dose-dependent)
- Direct GH receptor agonism (bypasses secretagogue pathway)
- Replacement therapy models; dose–response curves
- Bypasses endogenous regulatory feedback; expensive; requires daily dosing
- Bottom Line
- CJC-1295 no DAC uniquely balances sustained GH elevation with experimental reversibility. Critical for studies requiring both consistent anabolic signaling and the ability to observe recovery kinetics after discontinuation. DAC modification trades reversibility for permanence; sermorelin trades duration for pulsatility; recombinant hGH bypasses the secretagogue pathway entirely.
- The DAC vs no-DAC decision is the most consequential choice in GHRH analog selection. The drug affinity complex. A reactive chemical group added to the C-terminus of CJC-1295. Forms a covalent bond with lysine residues on albumin and, more problematically, with lysine residues on the GHRH receptor itself. This creates irreversible receptor occupancy: once bound, the peptide cannot be displaced or cleared, and GH secretion remains elevated until receptor turnover occurs through normal protein degradation and replacement (a process taking weeks). For chronic metabolic studies where permanent GH elevation is the goal, this is advantageous. For recovery research requiring washout phases, control groups, or longitudinal observation of repair kinetics post-intervention, it's disqualifying.
- Researchers working with compounds like CJC1295 Ipamorelin 5MG 5MG must specify which CJC variant is included. The pharmacological profiles are not interchangeable, and mislabeling creates data interpretation problems downstream.